FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer’s, enhancing patient convenience and safety.
• FDA approves Leqembi Iqlik on October 2023.
• Weekly subcutaneous injection for Alzheimer’s treatment.
• Enhances patient convenience and safety in care.
The U.S. Food and Drug Administration (FDA) approves the Biologics License Application for Leqembi Iqlik. This approval allows the drug to be administered as a weekly subcutaneous injection for Alzheimer’s disease treatment. The decision aims to enhance patient convenience and safety in care. Read more about the approval.
Why it matters
Alzheimer’s disease affects millions of people worldwide, and treatment options are limited. The approval of Leqembi Iqlik as a subcutaneous injection provides a more convenient administration method compared to traditional intravenous infusions. This could potentially improve adherence to treatment regimens and overall patient outcomes.
What’s next
With the FDA’s approval, healthcare providers can begin prescribing Leqembi Iqlik to eligible patients. The focus will now shift to monitoring the drug’s real-world effectiveness and safety profile. Additionally, further studies may explore its long-term impact on disease progression. For more insights on regulatory approvals, visit our Regulatory & Approvals section.